Tags

Type your tag names separated by a space and hit enter

Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients.
Neuromolecular Med. 2007; 9(3):249-54.NM

Abstract

High plasma homocysteine levels have been observed in Parkinson's disease (PD) patients treated with levodopa. In this study, we investigated the effects of C677T and A1298C MTHFR polymorphisms, in association with L-DOPA daily dose and vitamin status, on hyperhomocysteinemia development in PD patients. Plasma homocysteine and folate/vitamin B12 levels were assayed in 49 L-DOPA-treated PD patients, and compared with those of 86 healthy subjects. Genotyping for MTHFR polymorphisms was carried out by DG-DGGE. Homocysteine levels were significantly higher in patients than in controls (16.3 +/- 5.7 vs. 11.7 +/- 2.7 micromol/l, P < 0.01). No significant differences were found between patients and controls with regard to folate/vitamin B12 levels, and MTHFR allele distribution. The TT+AA genotype was significantly more frequent in PD patients than in controls (32.5% vs. 17.4%, P < 0.05), but not associated with an increased risk for PD (OR = 2.3, CI = 1.0-5.2). Further, patients carrier of this genotype exhibited a mild hyperhomocysteinemia (22.1 +/- 4.9 micromol/l), while a protective effect was observed in patients having the CC+AA genotype (11.2 +/- 1.6 micromol/l; OR = 0.19, CI = 0.06-0.59). Interestingly, homocysteine levels were also moderately increased in patients with CT heterozygous genotype, in the context of either AA or AC (14.5 +/- 3.6 micromol/l), in comparison to subjects with the CC + AA genotype. Finally, we did not find any significant association of combined C677T and A1298C MTHFR polymorphisms with an increased risk for hyperhomocysteinemia in PD patients. A better understanding of the role of homocysteine and MTHFR genotypes in PD is needed to reveal novel approaches for disease management.

Authors+Show Affiliations

Department of Biochemical, Physiological and Nutritional Sciences, University of Messina, Via Consolare Valeria, Policlinico Universitario, Messina, 98125, Italy. dcaccamo@unime.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17914182

Citation

Caccamo, D, et al. "Effect of MTHFR Polymorphisms On Hyperhomocysteinemia in Levodopa-treated Parkinsonian Patients." Neuromolecular Medicine, vol. 9, no. 3, 2007, pp. 249-54.
Caccamo D, Gorgone G, Currò M, et al. Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients. Neuromolecular Med. 2007;9(3):249-54.
Caccamo, D., Gorgone, G., Currò, M., Parisi, G., Di Iorio, W., Menichetti, C., Belcastro, V., Parnetti, L., Rossi, A., Pisani, F., Ientile, R., & Calabresi, P. (2007). Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients. Neuromolecular Medicine, 9(3), 249-54.
Caccamo D, et al. Effect of MTHFR Polymorphisms On Hyperhomocysteinemia in Levodopa-treated Parkinsonian Patients. Neuromolecular Med. 2007;9(3):249-54. PubMed PMID: 17914182.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients. AU - Caccamo,D, AU - Gorgone,G, AU - Currò,M, AU - Parisi,G, AU - Di Iorio,W, AU - Menichetti,C, AU - Belcastro,V, AU - Parnetti,L, AU - Rossi,A, AU - Pisani,F, AU - Ientile,R, AU - Calabresi,P, PY - 2006/12/19/received PY - 1999/11/30/revised PY - 2007/02/22/accepted PY - 2007/10/5/pubmed PY - 2007/12/28/medline PY - 2007/10/5/entrez SP - 249 EP - 54 JF - Neuromolecular medicine JO - Neuromolecular Med VL - 9 IS - 3 N2 - High plasma homocysteine levels have been observed in Parkinson's disease (PD) patients treated with levodopa. In this study, we investigated the effects of C677T and A1298C MTHFR polymorphisms, in association with L-DOPA daily dose and vitamin status, on hyperhomocysteinemia development in PD patients. Plasma homocysteine and folate/vitamin B12 levels were assayed in 49 L-DOPA-treated PD patients, and compared with those of 86 healthy subjects. Genotyping for MTHFR polymorphisms was carried out by DG-DGGE. Homocysteine levels were significantly higher in patients than in controls (16.3 +/- 5.7 vs. 11.7 +/- 2.7 micromol/l, P < 0.01). No significant differences were found between patients and controls with regard to folate/vitamin B12 levels, and MTHFR allele distribution. The TT+AA genotype was significantly more frequent in PD patients than in controls (32.5% vs. 17.4%, P < 0.05), but not associated with an increased risk for PD (OR = 2.3, CI = 1.0-5.2). Further, patients carrier of this genotype exhibited a mild hyperhomocysteinemia (22.1 +/- 4.9 micromol/l), while a protective effect was observed in patients having the CC+AA genotype (11.2 +/- 1.6 micromol/l; OR = 0.19, CI = 0.06-0.59). Interestingly, homocysteine levels were also moderately increased in patients with CT heterozygous genotype, in the context of either AA or AC (14.5 +/- 3.6 micromol/l), in comparison to subjects with the CC + AA genotype. Finally, we did not find any significant association of combined C677T and A1298C MTHFR polymorphisms with an increased risk for hyperhomocysteinemia in PD patients. A better understanding of the role of homocysteine and MTHFR genotypes in PD is needed to reveal novel approaches for disease management. SN - 1535-1084 UR - https://www.unboundmedicine.com/medline/citation/17914182/Effect_of_MTHFR_polymorphisms_on_hyperhomocysteinemia_in_levodopa_treated_Parkinsonian_patients_ L2 - https://dx.doi.org/10.1007/s12017-007-8006-x DB - PRIME DP - Unbound Medicine ER -